Overview

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total hip replacement surgery.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Darexaban
Enoxaparin
Criteria
Inclusion Criteria:

- Subjects is scheduled for elective primary total hip replacement surgery

- Written informed consent obtained before screening

Exclusion Criteria:

- Subject has history of deep vein thrombosis and/or pulmonary embolism

- Subject has a hemorrhagic disorder and/or coagulation disorder

- Subject has had clinically important bleeding occurred within 90 days prior to the
screening visit

- Subject has an acute bacterial endocarditis, retinopathy, hypertension, or
thrombocytopenia

- Subject is receiving anticoagulants/antiplatelet agents